FcRn-targeted therapeutics for the treatment of antibody-mediated autoimmune and albumin-mediated disease
AssigneeUniversity of Maryland, College Park
InventorsXiaoping Zhu, Xiaoyang Liu
Life of this patent
Estimating the term…
Abstract
HCMV US11 based therapeutics that can be used to target and reduce the activity of the FcRn protein are provided. Methods of treating auto-immune mediated and albumin-mediated diseases in a subject are provided that comprise administration of HCMV US11 protein, polypeptide fragments, or variants thereof, as well as methods for preventing, or treating, infections of HCMV through administration of a US11 inhibitor. US11 protein containing vaccine compositions are also provided for stimulation of an anti-US11 immune response for protection against HCMV infection.
Claims21
A method for inhibiting the activity of FcRn in a subject suffering from an antibody-mediated autoimmune disease or at risk for developing an antibody-mediated autoimmune disease, the method comprising administering to the subject, an effective amount of an engineered, purified, recombinantly expressed human cytomegalovirus (HCMV) US11 protein in a pharmaceutically acceptable form.
A vaccine formulation comprising an engineered, purified, recombinantly expressed HCMV US11 protein and a pharmaceutically acceptable carrier.
A kit comprising a pharmaceutical composition comprising an engineered, purified and recombinantly expressed HCMV US11 protein, and/or an engineered, purified HCMV US11-encoding nucleic acid.
A method for inhibiting the activity of FcRn in a subject suffering from an antibody-mediated autoimmune disease or at risk for developing an antibody-mediated autoimmune disease, the method comprising administering to the subject, an effective amount of an engineered, purified HCMV US11-encoding nucleic acid in a pharmaceutically acceptable form.
Dependencies are inferred from the claim text.